XtalPi Holdings Limited (2228)

Overview

XtalPi Holdings Limited operates as a research platform company across Mainland China, the United States, and other international markets. Founded in 2015 and headquartered in Shenzhen, China, the company is dedicated to advancing chemical synthesis and drug discovery through innovative technology solutions. XtalPi offers a range of products and engages in strategic collaborations, such as with Pfizer, to co-develop an AI-driven molecular simulation platform. The company formerly operated under the name QuantumPharm Inc. before rebranding to XtalPi Holdings Limited in December 2024. Its mission focuses on optimizing the drug discovery process and improving chemical research efficiencies globally.

Products and Services

• XmartChem: An intelligent synthesis workstation designed to automate the chemical synthesis process, thereby enhancing efficiency and accuracy in laboratory settings.
• ChemPlus: A desktop solid dispensing device that simplifies the handling of chemical solids, making it easier for researchers to perform experiments with precision.
• PatSight: An optical chemical structure extraction tool for patents that aids in identifying and analyzing chemical structures in patent documentation, facilitating research and innovation.
• XFEP: A software solution that enables rapid Free Energy Perturbation (FEP) calculations using cloud computing, streamlining the computational chemistry processes for drug development.
• XMolGen: A generative chemistry tool that assists researchers in the creation of novel molecular structures, aiding in the discovery of new compounds.
• Drug Discovery Solutions: This includes hit discovery, lead optimization, and biological capabilities aimed at advancing the drug development process effectively. The offerings are designed to streamline various stages of drug discovery.
• PepiX: A tool that generates stable peptides, which are crucial for therapeutic interventions and biological studies, enhancing the capabilities of drug development teams.
• Discovery Chemistry Solutions: This encompasses automation-aided chemical synthesis and focused library development, which facilitate high-throughput research and optimize chemical libraries for drug screening.
• XtalGazer: A solid-state research solution that provides insights into the physical properties of crystalline materials, crucial for pharmaceutical formulations and materials science.